Prof. Dr. rer. nat. Volker Schirrmacher
Wissenschaftlicher Leiter der Tumorimmunologie am IOZK
Krebsforscher und Immunologe
Prof. Dr. rer. nat. Volker Schirrmacher erhielt 1976 einen Ruf an das Deutsche Krebsforschungszentrum (DKFZ) in Heidelberg als Wissenschaftlicher Rat und Professor für Immunologie. 1979 habilitierte er sich in Immunologie in Heidelberg und 1986 wurde er ordentlicher Professor. Am DKFZ leitete er die Abteilung zelluläre Immunologie bis zu seiner Emeritierung 2008.
Seit 2008 ist er am IOZK Wissenschaftlicher Leiter der Tumorimmunologie. Sein Wissenschaftliches Œuvre umfasst fast 400 Veröffentlichungen in internationalen Fachzeitschriften.
1987 und 1988 war er Vorsitzender der Sektion Experimentelle Krebsforschung bei der Deutschen Krebsgesellschaft und 1989/80 Präsident der Metastasis Research Society. 2003 und 2004 vertrat er Deutschland bei der European Association of Cancer Research (EACR). Von 2009 bis 2011 war er Präsident der Europäischen Gesellschaft für Angewandte Immunologie e.V. (EGAI).
1982 erhielt er den Aronson-Preis und den Meyenburg-Preis und 1988 den Deutschen Krebspreis.
Er ist ein international anerkannter Pionier der Immuntherapie bei Krebs mit dem Schwerpunkt onkolytische Viren. Gemeinsam mit den Naturwissenschaftlern und Ärzten am IOZK arbeitet er an der systematischen Integration neuer wissenschaftlicher Erkenntnisse zur Weiterentwicklung der IOZK-Immuntherapie.
„Viren sind als Auslöser verschiedener Krankheiten bekannt. Weniger bekannt ist jedoch, dass bestimmte Viren für die Behandlung von Krebs eingesetzt werden. Vor über 100 Jahren beobachteten Ärzte erstmals, dass Patienten nach Virusinfektionen von ihrem Krebsleiden geheilt waren.“
Prof. Dr. rer. nat. Volker Schirrmacher
Sammlung: Wissenschaftliche Beiträge und internationale Publikationen von Volker Schirrmacher
Weitere Informationen zu diesem Thema:
This post is also available in: Russisch
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
/in Dendritic Cells, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-07-23 / Biomedicines 2020 Jul;8(8)PMID: 32717895 Journal: Biomedicines (volume: 8, issue: 8, Biomedicines 2020 Jul;8(8)) Published: 2020-07-23 Authors: Schirrmacher V, Sprenger T, Stuecker W, Van Gool SW ABSTRACT At times of personalized and individualized medicine the concept of randomized- controlled clinical trials (RCTs) is being questioned. This review article explains principles of evidence-based medicine in oncology and shows an […]
Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
/in Dendritic Cells, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-06-30 / Expert Rev Anticancer Ther 2020 Jun;:1-8PMID: 32600076 Journal: Expert review of anticancer therapy (volume: , issue: , Expert Rev Anticancer Ther 2020 Jun;:1-8) Published: 2020-06-30 Authors: Sprenger T, Schirrmacher V, Stücker W, van Gool SW ABSTRACT INTRODUCTION: Prospective double-blind placebo-controlled randomized clinical trials (RCTs) are considered standard for the proof of the efficacy of oncologic therapies. Molecular methods have provided […]
IOZK Analyse belegt gute Verträglichkeit der IOZK Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG)
/in IOZK Veröffentlichungen /von IOZKDas Team des IOZK veröffentlicht mit einer internationalen Gruppe von Wissenschaftlern aus Deutschland, der Schweiz und den USA eine retrospektive Analyse zur Anwendung der IOZK-Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG). Es belegt die gute Verträglichkeit und möglichen klinischen Nutzen der Kombination aus Impfung mit Dendritischen Zellen, onkolytischer Virotherapie mit dem Newcastle Disease Virus und […]
Prof. Dr. Volker Schirrmacher veröffentlicht zwei wegweisende Übersichtsartikel zur Immuntherapie
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKProf. Dr. Volker Schirrmacher veröffentlicht zwei wegweisende Übersichtsartikel zu besonders bemerkenswerten Eigenschaften der Immuntherapie: die hervorragende Verträglichkeit von DC-Vakzinen und onkolytischer Virotherapie im Vergleich zu anderen systemischen Behandlungsformen, die auf einer deutlich niedrigeren Nebenwirkungsrate beruht Artikel öffnen die langfristige Wirksamkeit von durch Virus Infektion modifizierten anti-Krebs Impfstoffen. Der Wirkmechanismus beruhe auf der Entwicklung eines immunologischen […]
New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2020-03-06 / Biomedicines 2020 Mar;8(3)PMID: 32155856 Journal: Biomedicines (volume: 8, issue: 3, Biomedicines 2020 Mar;8(3)) Published: 2020-03-06 Authors: Schirrmacher V ABSTRACT The topic is how to achieve long-term protective anti-tumor immunity by anti-cancer vaccination and what are its mechanisms. Cancer vaccines should instruct the immune system regarding relevant cancer targets and contain signals for innate immunity activation. Of central […]
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-08-30 / Biomedicines 2019 Aug;7(3)PMID: 31480379 Journal: Biomedicines (volume: 7, issue: 3, Biomedicines 2019 Aug;7(3)) Published: 2019-08-30 Authors: Schirrmacher V, van Gool S, Stuecker W ABSTRACT Resistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus (NDV) as a […]
Professor Volker Schirrmacher vom Kölner IOZK eröffnet die Tagung an der Universität zu Kiel mit seinem Vortrag zur Erforschung onkolytischer Viren im Zusammenhang der individuellen Krebs-Immuntherapie.
/in IOZK bei Fachtagungen /von IOZKKiel Oncology Network veranstaltet bundesweit besetztes Symposium zur Tumorimmunologie an der CAU Am 26. April 2019 tagen rund 80 Krebsforschende aus ganz Deutschland beim 3. Kiel Oncology Network-Symposium im Kieler Wissenschaftszentrum. Thema der diesjährigen Veranstaltung ist die Tumorimmunologie und damit verbundene Chancen und Herausforderungen für künftige Immuntherapien. Im Kern dieses Teilgebiets der Onkologie steht die […]
International Journal of Oncology: „Von der Chemotherapie zur biologischen Therapie“, Prof. Dr. Volker Schirrmacher
/in IOZK In der Presse /von IOZK„Von der Chemotherapie zur biologischen Therapie: Eine Überprüfung neuartiger Konzepte zur Reduktion der Nebenwirkungen bei einer systemischen Krebsbehandlung“ – so lautet der Titel der wissenschaftlichen Veröffentlichung von Prof. Dr. Volker Schirrmacher im International Journal of Oncology. Die Nebenwirkungen von Chemotherapien sind oft schwerwiegend. In letzter Zeit wurde dem Immunsystem der Patienten und seiner Aktivierung durch biologische […]
IOZK-Artikel über Heilversuche bei Glioblastom im Fachorgan: „Austin Oncology Case Report“
/in IOZK Veröffentlichungen /von rootDie IOZK-Arbeitsgruppe publizierte einen wissenschaftlichen Artikel im Fachorgan „Austin Oncology Case Report“. In dieser Arbeit wurden retrospektiv Patienten mit Glioblastom im Rahmen individueller Heilversuche untersucht – unter der tumorspezifischen Immunmodulation mittels modulierter Elektro-Hyperthermie in Kombination mit onkolytischer Virotherapie – zusätzlich zur Chemotherapie mit Temodal. Die adjuvante Therapie gibt Hinweise auf einen besseren Therapieeffekt, wenn neben […]
IOZK Vortrag: Modulierte Elektro-Hyperthermie bei Kindern mit DIPG, Konferenz der ESHO, Charité Berlin
/in IOZK bei Fachtagungen, IOZK Meldungen /von IOZKDas IOZK nahm an der jährlichen Konferenz der ESHO (European Society for Hyperthermic Oncology) teil, die an der Berliner Universitätsklinik – Charité stattfand. Thema des IOZK-Vortrags war die modulierte Elektro-Hyperthermie als Teil der Behandlung von Kindern mit DIPG, einem aggressiven Hirntumor (Hyperthermia as part of multimodal immunotherapy for children with DIPG, S. van Gool, J. Makalowski, V. Schirrmacher, […]
Buch Veröffentlichung von Prof. Dr. Schirrmacher: Quo vadis cancer therapy
/in IOZK Meldungen, IOZK Veröffentlichungen /von IOZKIOZK Artikel im International Journal of Molecular Sciences von Prof. Schirrmacher über die Rolle des Newcastle Disease Virus im Rahmen der Tumorimpfung,
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKIm Fachorgan „International Journal of Molecular Sciences“ wurde ein Beitrag von Prof. Dr. rer. nat. Volker Schirrmacher veröffentlicht, der sich mit der Rolle des Newcastle Disease Virus im Rahmen der Tumorimpfung beschäftigt. Immunobiology of Newcastle Disease Virus and its use for prophylactic vaccination in poultry and as adjuvant for therapeutic vaccination in cancer patients
Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients
/in International Publications, Newcastle Disease Virus /von 2017-05-20 / Int J Mol Sci 2017 May;18(5)PMID: 28531117 Journal: International journal of molecular sciences (volume: 18, issue: 5, Int J Mol Sci 2017 May;18(5)) Published: 2017-05-20 Authors: Schirrmacher V ABSTRACT Newcastle disease (ND) is one of the most important diseases of poultry worldwide. In the last decades, molecular research has gained a lot of new information about its causative agent, (NDV). […]
IOZK Artikel von Prof. Schirrmacher in „Deutsche Zeitschrift für Onkologie“ über die Grundlagen der Immuntherapie
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKIn „Deutsche Zeitschrift für Onkologie“ erscheint ein Fachbeitrag von Prof. Schirrmacher. Es werden die Grundlagen der Immuntherapie erklärt und an Beispielen aufgezeigt, welche Strategien besonders erfolgversprechende Resultate erzielt haben. Immuntherapie: eine biologische Form der Krebstherapie „Fortschritte in der Krebsbehandlung sind dringend erforderlich, um die Effektivität der Behandlung zu steigern. In den vergangenen 20 Jahren hat sich […]
IOZK Artikel im Austin Oncology Case Reports über Krebsimpfstoffe
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKIm amerikanischen Fachorgan Austin Oncology Case Reports publiziert das IOZK in der Sonderausgabe zu Krebsimpfstoffen einen Beitrag, der die Strategie der spezifischen Immuntherapie beschreibt und erläutert. A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination
Artikel von Prof Schirrmacher in Biomedicines: „Fifty Years of Clinical Application of Newcastle Disease Virus“
/in IOZK Meldungen, IOZK Veröffentlichungen /von IOZKIn einem englischen Fachartikel bietet Prof. Schirrmacher einen Überblick zu „50 Jahre Klinische Anwendung des Newcastle Disease Virus“, erschienen in Biomedicines. Der erste Bericht erschien bereits 1964, in dem die Beobachtungen und Ergebnisse einer Krebsbehandlung veröffentlicht wurden, bei der das onkolytische Virus zum Einsatz kam. Fifty Years of Clinical Application of Newcastle Disease Virus
Fachbeitrag von Prof. Schirrmacher zur Effizienz und Effektivität der Krebsbehandlung, Wiener klinisches Magazin
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKIm „Wiener klinisches Magazin“ erscheint ein Fachbeitrag von Prof. Schirrmacher zur Effizienz und Effektivität der Krebsbehandlung. Chemotherapie und/oder Immuntherapie?
Expertenbericht von Prof. Dr. Schirrmacher, Wiener klinisches Magazin
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKProf. Schirrmacher publiziert einen Expertenbericht zum therapeutischen Einsatz onkolytischer Viren am Beispiel Newcastle Disease Virus. Durchbrechen von Therapieresistenzen
Bericht von Prof. Dr. Schirrmacher im International Journal of Oncology zu den Erkenntnissen der Tumor-reaktiven T-Zell-Memory im Knochenmark
/in IOZK Veröffentlichungen /von IOZKDer wissenschaftliche Leiter der Tumorimmunologie im IZOK Prof. Schirrmacher publiziert im „International Journal of Oncology“ einen Bericht zu den Erkenntnissen der Tumor-reaktiven T-Zell-Memory im Knochenmark und dem daraus resultierenden therapeutischen Potenzial. Cancer-reactive memory T cells from bone marrow: Spontaneous induction and therapeutic potential (Review)
Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance
/in International Publications, Newcastle Disease Virus /von 2015-10-05 / Expert Opin Biol Ther 2015;15(12):1757-71PMID: 26436571 Journal: Expert opinion on biological therapy (volume: 15, issue: 12, Expert Opin Biol Ther 2015;15(12):1757-71) Published: 2015-10-05 Authors: Schirrmacher V ABSTRACT INTRODUCTION: Oncolytic viruses (OVs) selectively replicate in tumor cells and cause cancer cell death. Most OVs in clinical studies are genetically engineered. In contrast, the avian Newcastle disease virus (NDV) is a […]
IOZK Fallstudie zum Langzeitüberleben einer Patientin mit Brustkrebs
/in IOZK Meldungen, IOZK Veröffentlichungen /von IOZKIOZK Fallstudie zum Langzeitüberleben einer Patientin mit Brustkrebs Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
Beitrag von Prof. Dr. Schirrmacher in der Wiener medizinischen Wochenschrift „Skriptum“
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKEin Beitrag von Prof. Schirrmacher in der Wiener medizinische Wochenschrift „Skriptum“ Therapeutischer Einsatz onkolytischer Viren
Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
/in Breast Cancer, Dendritic Cells, Hyperthermia, International Publications, Newcastle Disease Virus /von 2015-05-28 / Immunotherapy 2015;7(8):855-60PMID: 26020523 Journal: Immunotherapy (volume: 7, issue: 8, Immunotherapy 2015;7(8):855-60) Published: 2015-05-28 Authors: Schirrmacher V, Stücker W, Lulei M, Bihari AS, Sprenger T ABSTRACT Liver metastases in breast cancer are associated with a poor prognosis. We report long-term survival of a patient with breast cancer and liver metastases. After operation the patient declined further standard […]
Prof. Dr. Schirrmacher veröffentlicht E-Book: Harnessing Oncolytic Virus-mediated Antitumor Immunity
/in IOZK Meldungen, IOZK Veröffentlichungen /von IOZKProf. Schirrmacher hat ein E-Book über Virotherapie bei Tumorerkrankungen herausgegeben. Harnessing Oncolytic Virus-Mediated Anti-Tumor Immunity
Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
/in Dendritic Cells, Hyperthermia, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-2406PMID: 25364402 Journal: Oncology letters (volume: 8, issue: 6, Oncol Lett 2014 Dec;8(6):2403-2406) Published: 2014-10-06 Authors: Schirrmacher V, Bihari AS, Stücker W, Sprenger T ABSTRACT The present study reports the case of a patient with hormone-refractory metastatic prostate cancer who had failed standard therapy, but then achieved complete remission following combined treatment with local hyperthermia […]
Strong T‑cell costimulation can reactivate tumor antigen‑specific T cells in late‑stage metastasized colorectal carcinoma patients: results from a phase Ⅰ clinical study
/in International Publications, Newcastle Disease Virus /von 2014-10-06 / Int. J. Oncol. 2015 Jan;46(1):71-7PMID: 25354198 Journal: International journal of oncology (volume: 46, issue: 1, Int. J. Oncol. 2015 Jan;46(1):71-7) Published: 2014-10-06 Authors: Schirrmacher V, Schlude C, Weitz J, Beckhove P ABSTRACT T‑cell costimulation is necessary to induce a response of naïve T cells. Whether T‑cell costimulation can also cause reactivation of unreactive, possibly anergized memory T cells (MTCs) from late‑stage cancer […]
Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2014-09-11 / Front Oncol 2014;4:224PMID: 25309868 Journal: Frontiers in oncology (volume: 4, issue: , Front Oncol 2014;4:224) Published: 2014-09-11 Authors: Schirrmacher V, Fournier P ABSTRACT This paper focuses on oncolytic Newcastle disease virus (NDV). This paper summarizes (i) the peculiarities of this virus as an anti-cancer and immune stimulatory agent and (ii) the approaches to further harness this virus […]
Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-30PMID: 24219122 Journal: Expert review of vaccines (volume: 13, issue: 1, Expert Rev Vaccines 2014 Jan;13(1):117-30) Published: 2014-01-01 Authors: Schirrmacher V, Fournier P, Schlag P ABSTRACT Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Surgery remains the primary curative treatment but nearly 50% of patients relapse as consequence of micrometastatic […]
Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-75PMID: 24833054 Journal: Biology (volume: 2, issue: 3, Biology (Basel) 2013 Jul;2(3):936-75) Published: 2013-07-02 Authors: Fournier P, Schirrmacher V ABSTRACT Oncolytic viruses (OVs) replicate selectively in tumor cells and exert anti-tumor cytotoxic activity. Among them, Newcastle Disease Virus (NDV), a bird RNA virus of the paramyxovirus family, appears outstanding. Its anti-tumor effect is based on: […]
Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
/in International Publications, Newcastle Disease Virus /von 2013-02-01 / BioDrugs 2013 Feb;27(1):35-53PMID: 23329400 Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (volume: 27, issue: 1, BioDrugs 2013 Feb;27(1):35-53) Published: 2013-02-01 Authors: Fournier P, Schirrmacher V ABSTRACT Monoclonal anti-tumor antibodies (mAbs) that are clinically effective usually recruit, via their constant fragment (Fc) domain, Fc receptor (FcR)-positive accessory cells of the immune system and engage these additionally […]
Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
/in International Publications, Newcastle Disease Virus /von 2012-01-01 / Methods Mol. Biol. 2012;797:177-204PMID: 21948477 Journal: Methods in molecular biology (Clifton, N.J.) (volume: 797, issue: , Methods Mol. Biol. 2012;797:177-204) Published: 2012-01-01 Authors: Fournier P, Bian H, Szeberényi J, Schirrmacher V ABSTRACT Newcastle disease virus (NDV), a bird paramyxovirus, is an antitumor agent which has shown benefits to cancer patients. Its antineoplastic efficacy appears to be associated with […]
Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
/in International Publications, Newcastle Disease Virus /von 2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-50PMID: 22102168 Journal: International journal of oncology (volume: 40, issue: 3, Int. J. Oncol. 2012 Mar;40(3):840-50) Published: 2011-11-16 Authors: Fournier P, Arnold A, Wilden H, Schirrmacher V ABSTRACT Newcastle disease virus (NDV) is a negative sense RNA paramyxovirus of birds which in human tumor cells, in contrast to human non-tumor cells, has shown replication competence […]
Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-98PMID: 21971670 Journal: International journal of oncology (volume: 40, issue: 1, Int. J. Oncol. 2012 Jan;40(1):287-98) Published: 2011-10-04 Authors: Fournier P, Wilden H, Schirrmacher V ABSTRACT Newcastle disease virus (NDV) is an avian paramyxovirus with oncolytic properties which shows promising effects in the treatment of cancer. Anti-cancer effects are due to the virus ability: i) […]
Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2011-05-09 / Int. J. Oncol. 2011 Aug;39(2):493-504PMID: 21567079 Journal: International journal of oncology (volume: 39, issue: 2, Int. J. Oncol. 2011 Aug;39(2):493-504) Published: 2011-05-09 Authors: Wilden H, Schirrmacher V, Fournier P ABSTRACT Newcastle disease virus (NDV) is an interesting agent for activating innate immune activity in macrophages including secretion of TNF-α and IFN-α, upregulation of TRAIL and activation of NF-κB and […]
Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-29PMID: 21424118 Journal: International journal of oncology (volume: 38, issue: 6, Int. J. Oncol. 2011 Jun;38(6):1719-29) Published: 2011-03-17 Authors: Fournier P, Aigner M, Schirrmacher V ABSTRACT Fusion proteins combining antibodies with cytokines such as IL-2 and GM-CSF appear to be promising reagents for tumor therapy. In this study, we combined such immunocytokines with the tumor […]
Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity
/in International Publications, Newcastle Disease Virus /von 2010-12-18 / Vaccine 2011 Feb;29(6):1185-93PMID: 21172381 Journal: Vaccine (volume: 29, issue: 6, Vaccine 2011 Feb;29(6):1185-93) Published: 2010-12-18 Authors: Ni J, Galani IE, Cerwenka A, Schirrmacher V, Fournier P ABSTRACT A plasmid encoding the Hemagglutinin-Neuraminidase (HN) protein of Newcastle Disease Virus (pHN) was tested for its capacity to stimulate innate anti-tumor activity in tumor-bearing mice. We observed that application of […]
Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25
/in International Publications, Newcastle Disease Virus /von 2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-52PMID: 21042712 Journal: International journal of oncology (volume: 37, issue: 6, Int. J. Oncol. 2010 Dec;37(6):1439-52) Published: 2010-12-01 Authors: Fournier P, Aigner M, Schirrmacher V ABSTRACT T-cell receptor engagement by peptide/MHC complexes constitutes the main signal for the activation of naive T cells, but for a productive generation and maintenance of effector cells, full activation […]
Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine
/in International Publications, Newcastle Disease Virus /von 2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-17PMID: 20878068 Journal: International journal of oncology (volume: 37, issue: 5, Int. J. Oncol. 2010 Nov;37(5):1203-17) Published: 2010-11-01 Authors: Fournier P, Aigner M, Schirrmacher V ABSTRACT Tumor vaccines have to provide several signals for T cell activation. Among them, signal 1 (through TCR/CD3) and signal 2 (through CD28) are the most important. We herein describe […]
The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
/in International Publications, Newcastle Disease Virus /von 2010-08-13 / Vaccine 2010 Oct;28(42):6891-900PMID: 20709006 Journal: Vaccine (volume: 28, issue: 42, Vaccine 2010 Oct;28(42):6891-900) Published: 2010-08-13 Authors: Ni J, Schirrmacher V, Fournier P ABSTRACT Plasmid-encoded DNA vaccine is a novel and potentially powerful tool for cancer therapy. Since the strength of immune responses induced by DNA vaccine is usually rather low, a major goal in DNA vaccine development […]
Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-22PMID: 19785053 Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology (volume: 14 Suppl 1, issue: , J BUON 2009 Sep;14 Suppl 1:S111-22) Published: 2009-09-01 Authors: Fournier P, Arnold A, Schirrmacher V ABSTRACT PURPOSE: Dendritic cell (DC)-based tumor vaccines have been tested extensively to treat cancer patients. However, the results of […]
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase
/in International Publications, Newcastle Disease Virus /von 2009-06-10 / J. Virol. 2009 Aug;83(16):8108-21PMID: 19515783 Journal: Journal of virology (volume: 83, issue: 16, J. Virol. 2009 Aug;83(16):8108-21) Published: 2009-06-10 Authors: Jarahian M, Watzl C, Fournier P, Arnold A, Djandji D, Zahedi S, Cerwenka A, Paschen A, Schirrmacher V, Momburg F ABSTRACT The avian paramyxovirus Newcastle disease virus (NDV) selectively replicates in tumor cells and is known to stimulate […]
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus
/in International Publications, Newcastle Disease Virus /von 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-82PMID: 19287954 Journal: International journal of oncology (volume: 34, issue: 4, Int. J. Oncol. 2009 Apr;34(4):971-82) Published: 2009-04-01 Authors: Wilden H, Fournier P, Zawatzky R, Schirrmacher V ABSTRACT Newcastle Disease Virus (NDV) is an avian paramyxovirus with anti-neoplastic and immune-stimulatory properties which has raised considerable interest for cancer therapy. To better understand the molecular nature […]
Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-62PMID: 19287952 Journal: International journal of oncology (volume: 34, issue: 4, Int. J. Oncol. 2009 Apr;34(4):951-62) Published: 2009-04-01 Authors: Pfirschke C, Schirrmacher V ABSTRACT Oncolytic virotherapy, a new type of cancer therapy involving viruses with oncolytic and immunostimulatory potential, is based on tumor selective viral replication, resulting in a specific lysis of tumor cells. Effective […]
Randomized clinical studies of anti-tumor vaccination: state of the art in 2008
/in Dendritic Cells, International Publications /von 2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-66PMID: 19093773 Journal: Expert review of vaccines (volume: 8, issue: 1, Expert Rev Vaccines 2009 Jan;8(1):51-66) Published: 2009-01-01 Authors: Fournier P, Schirrmacher V ABSTRACT This review elucidates state-of-the-art clinical studies on active specific immunotherapy with tumor vaccines. It refers solely to randomized studies and has a special focus on patient’s survival, the most important parameter […]
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer
/in International Publications, Newcastle Disease Virus /von 2009-01-01 / Methods Mol. Biol. 2009;542:565-605PMID: 19565923 Journal: Methods in molecular biology (Clifton, N.J.) (volume: 542, issue: , Methods Mol. Biol. 2009;542:565-605) Published: 2009-01-01 Authors: Schirrmacher V, Fournier P ABSTRACT This review deals with the avian paramyxovirus Newcastle disease virus (NDV) and describes properties that explain its oncolytic activity, its tumor-selective replication behavior, and its immune-stimulatory capacity with human cells. […]
Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
/in Breast Cancer, Dendritic Cells, International Publications /von 2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-900PMID: 18998129 Journal: Cancer immunology, immunotherapy : CII (volume: 58, issue: 6, Cancer Immunol. Immunother. 2009 Jun;58(6):887-900) Published: 2008-11-08 Authors: Schuetz F, Ehlert K, Ge Y, Schneeweiss A, Rom J, Inzkirweli N, Sohn C, Schirrmacher V, Beckhove P ABSTRACT BACKGROUND: Breast cancer patients frequently harbour tumour-reactive memory T cells in their bone marrow (BM) but […]
Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2
/in International Publications, Newcastle Disease Virus /von 2008-10-01 / Int. J. Oncol. 2008 Oct;33(4):823-32PMID: 18813797 Journal: International journal of oncology (volume: 33, issue: 4, Int. J. Oncol. 2008 Oct;33(4):823-32) Published: 2008-10-01 Authors: Janke M, Peeters B, Zhao H, de Leeuw O, Moorman R, Arnold A, Ziouta Y, Fournier P, Schirrmacher V ABSTRACT A new recombinant (rec) Newcastle disease virus (NDV) with incorporated human interleukin 2 (IL-2) as foreign […]
Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy
/in International Publications, Newcastle Disease Virus /von 2008-06-05 / Virus Res. 2008 Sep;136(1-2):75-80PMID: 18538434 Journal: Virus research (volume: 136, issue: 1-2, Virus Res. 2008 Sep;136(1-2):75-80) Published: 2008-06-05 Authors: Zhao H, Janke M, Fournier P, Schirrmacher V ABSTRACT A recombinant Newcastle disease virus (NDV) containing human interleukin-2 (IL-2) gene was generated by applying reverse genetics technique and further evaluated for its suitability to express and deliver IL-2 for […]
Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer
/in Colorectal Cancer, International Publications /von 2008-06-03 / Ann. Surg. Oncol. 2008 Aug;15(8):2310-7PMID: 18521684 Journal: Annals of surgical oncology (volume: 15, issue: 8, Ann. Surg. Oncol. 2008 Aug;15(8):2310-7) Published: 2008-06-03 Authors: Wagner P, Koch M, Nummer D, Palm S, Galindo L, Autenrieth D, Rahbari N, Schmitz-Winnenthal FH, Schirrmacher V, Büchler MW, Beckhove P, Weitz J ABSTRACT BACKGROUND: Tumor-infiltrating T lymphocytes (TIL) play an important role in primary […]
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
/in Colorectal Cancer, International Publications, Newcastle Disease Virus /von 2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-9PMID: 18488223 Journal: Cancer immunology, immunotherapy : CII (volume: 58, issue: 1, Cancer Immunol. Immunother. 2009 Jan;58(1):61-9) Published: 2008-05-17 Authors: Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM ABSTRACT PURPOSE: Metastatic disease is a major cause of mortality in colorectal cancer patients. Even after complete resection of isolated liver metastases, recurrence […]
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins
/in International Publications, Newcastle Disease Virus /von 2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):777-89PMID: 18360705 Journal: International journal of oncology (volume: 32, issue: 4, Int. J. Oncol. 2008 Apr;32(4):777-89) Published: 2008-04-01 Authors: Aigner M, Janke M, Lulei M, Beckhove P, Fournier P, Schirrmacher V ABSTRACT T cell costimulation has great therapeutic potential if it can be optimized and controlled. To achieve this, we engineered T cell-activating fusion proteins […]
Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007
/in International Publications, Newcastle Disease Virus /von 2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7PMID: 18270701 Journal: Cancer immunology, immunotherapy : CII (volume: 57, issue: 9, Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7) Published: 2008-02-13 Authors: Schirrmacher V, Beckhove P, Fournier P, Umansky V ABSTRACT Open in PubMed
Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application
/in International Publications, Newcastle Disease Virus /von 2007-11-01 / Int. J. Oncol. 2007 Nov;31(5):1009-19PMID: 17912426 Journal: International journal of oncology (volume: 31, issue: 5, Int. J. Oncol. 2007 Nov;31(5):1009-19) Published: 2007-11-01 Authors: Apostolidis L, Schirrmacher V, Fournier P ABSTRACT Several strains of the Newcastle disease virus (NDV) have raised considerable interest in recent years for clinical application because of their oncolytic properties. In this study we characterized virological, […]
Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
/in International Publications, Newcastle Disease Virus /von 2007-10-04 / Gene Ther. 2007 Dec;14(23):1639-49PMID: 17914407 Journal: Gene therapy (volume: 14, issue: 23, Gene Ther. 2007 Dec;14(23):1639-49) Published: 2007-10-04 Authors: Janke M, Peeters B, de Leeuw O, Moorman R, Arnold A, Fournier P, Schirrmacher V ABSTRACT This is the first report describing recombinant (rec) Newcastle disease virus (NDV) as vector for gene therapy of cancer. The gene encoding granulocyte/macrophage […]
Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma
/in International Publications, Pancreatic Cancer /von 2007-07-24 / J. Natl. Cancer Inst. 2007 Aug;99(15):1188-99PMID: 17652277 Journal: Journal of the National Cancer Institute (volume: 99, issue: 15, J. Natl. Cancer Inst. 2007 Aug;99(15):1188-99) Published: 2007-07-24 Authors: Nummer D, Suri-Payer E, Schmitz-Winnenthal H, Bonertz A, Galindo L, Antolovich D, Koch M, Büchler M, Weitz J, Schirrmacher V, Beckhove P ABSTRACT BACKGROUND: Regulatory T (Treg) cells have been detected in human […]
Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ
/in Colorectal Cancer, International Publications /von 2006-12-01 / Ann. Surg. 2006 Dec;244(6):986-92; discussion 992-3PMID: 17122624 Journal: Annals of surgery (volume: 244, issue: 6, Ann. Surg. 2006 Dec;244(6):986-92; discussion 992-3) Published: 2006-12-01 Authors: Koch M, Beckhove P, Op den Winkel J, Autenrieth D, Wagner P, Nummer D, Specht S, Antolovic D, Galindo L, Schmitz-Winnenthal FH, Schirrmacher V, Büchler MW, Weitz J ABSTRACT OBJECTIVE: To examine whether tumor-selective infiltration, activation, […]
Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence
/in International Publications, Newcastle Disease Virus /von 2006-07-15 / Int. J. Cancer 2006 Jul;119(2):328-38PMID: 16470838 Journal: International journal of cancer (volume: 119, issue: 2, Int. J. Cancer 2006 Jul;119(2):328-38) Published: 2006-07-15 Authors: Fiola C, Peeters B, Fournier P, Arnold A, Bucur M, Schirrmacher V ABSTRACT To investigate tumor-selective viral replication, we compared several tumorigenic human cell lines to nontumorigenic human cells from the blood for the sensitivity to […]
A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
/in International Publications, Newcastle Disease Virus /von 2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-67PMID: 16108015 Journal: International journal of cancer (volume: 118, issue: 3, Int. J. Cancer 2006 Feb;118(3):658-67) Published: 2006-02-01 Authors: Haas C, Lulei M, Fournier P, Arnold A, Schirrmacher V ABSTRACT We recently reported on newly designed virus-targeted bispecific CD3- and CD28-binding molecules for human T-cell activation. When bound via one arm to a human virus-modified […]
Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein
/in International Publications, Newcastle Disease Virus /von 2005-08-01 / Int. J. Oncol. 2005 Aug;27(2):377-84PMID: 16010418 Journal: International journal of oncology (volume: 27, issue: 2, Int. J. Oncol. 2005 Aug;27(2):377-84) Published: 2005-08-01 Authors: Bian H, Fournier P, Peeters B, Schirrmacher V ABSTRACT Previously we have demonstrated that a recombinant Newcastle disease virus (NDV) carrying the transgene EGFP can be retargeted to IL-2 receptor positive tumor cells by a bispecific […]
T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine
/in International Publications, Newcastle Disease Virus /von 2005-03-31 / Vaccine 2005 Mar;23(19):2439-53PMID: 15752830 Journal: Vaccine (volume: 23, issue: 19, Vaccine 2005 Mar;23(19):2439-53) Published: 2005-03-31 Authors: Haas C, Lulei M, Fournier P, Arnold A, Schirrmacher V ABSTRACT The aim was to develop T cell costimulatory molecules that are broadly applicable to augment anti-tumor immune responses upon application of a virus-modified tumor vaccine to cancer patients. We generated […]
Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2005-03-01 / Cancer Gene Ther. 2005 Mar;12(3):295-303PMID: 15605075 Journal: Cancer gene therapy (volume: 12, issue: 3, Cancer Gene Ther. 2005 Mar;12(3):295-303) Published: 2005-03-01 Authors: Bian H, Fournier P, Moormann R, Peeters B, Schirrmacher V ABSTRACT We developed a novel strategy to target recombinant Newcastle disease virus (NDV) to tumor cells for gene therapy. Modifying the virus with a bispecific fusion protein […]
Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein
/in International Publications, Newcastle Disease Virus /von 2005-02-01 / Int. J. Oncol. 2005 Feb;26(2):431-9PMID: 15645128 Journal: International journal of oncology (volume: 26, issue: 2, Int. J. Oncol. 2005 Feb;26(2):431-9) Published: 2005-02-01 Authors: Bian H, Fournier P, Moormann R, Peeters B, Schirrmacher V ABSTRACT Much interest exists presently in development of vectors for gene therapy of tumors based on RNA viruses because these viruses replicate in the cytoplasm and […]
Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells
/in International Publications, Newcastle Disease Virus /von 2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-61PMID: 15520216 Journal: Cancer research (volume: 64, issue: 21, Cancer Res. 2004 Nov;64(21):8057-61) Published: 2004-11-01 Authors: Karcher J, Dyckhoff G, Beckhove P, Reisser C, Brysch M, Ziouta Y, Helmke BH, Weidauer H, Schirrmacher V, Herold-Mende C ABSTRACT Prognosis of patients with advanced head and neck squamous cell carcinomas (HNSCC) is still poor. Therefore, we analyzed […]
Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory
/in International Publications, Newcastle Disease Virus /von 2004-10-30 / Cancer Immunol. Immunother. 2005 Jun;54(6):587-98PMID: 15838708 Journal: Cancer immunology, immunotherapy : CII (volume: 54, issue: 6, Cancer Immunol. Immunother. 2005 Jun;54(6):587-98) Published: 2004-10-30 Authors: Schirrmacher V ABSTRACT For active specific immunotherapy of cancer patients, we designed the autologous virus-modified tumor cell vaccine ATV-NDV. The rationale of this vaccine is to link multiple tumor-associated antigens (TAAs) from individual patient-derived tumor […]
Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-81PMID: 15452186 Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (volume: 22, issue: 21, J. Clin. Oncol. 2004 Nov;22(21):4272-81) Published: 2004-09-27 Authors: Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Geletneky K, Ahmadi R, Schuele-Freyer R, Kremer P, Ranaie G, Matejic D, Bauer H, Kiessling M, Kunze S, […]
High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules
/in International Publications, Newcastle Disease Virus /von 2004-08-01 / Int. J. Oncol. 2004 Aug;25(2):293-302PMID: 15254725 Journal: International journal of oncology (volume: 25, issue: 2, Int. J. Oncol. 2004 Aug;25(2):293-302) Published: 2004-08-01 Authors: Zeng J, Fournier P, Schirrmacher V ABSTRACT For functional studies, the hemagglutinin-neuraminidase (HN) and the fusion protein (F) of Newcastle disease virus (NDV) were expressed in BHK cells using two vectors which are based on the […]
Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus
/in International Publications, Newcastle Disease Virus /von 2004-03-01 / Int. J. Oncol. 2004 Mar;24(3):623-34PMID: 14767547 Journal: International journal of oncology (volume: 24, issue: 3, Int. J. Oncol. 2004 Mar;24(3):623-34) Published: 2004-03-01 Authors: Fournier P, Zeng J, Von Der Lieth CW, Washburn B, Ahlert T, Schirrmacher V ABSTRACT Newcastle disease virus (NDV) is an avian paramyxovirus with replication competence in human tumor cells and interesting anti-neoplastic and immune stimulatory […]
TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2003-02-15 / J. Immunol. 2003 Feb;170(4):1814-21PMID: 12574346 Journal: Journal of immunology (Baltimore, Md. : 1950) (volume: 170, issue: 4, J. Immunol. 2003 Feb;170(4):1814-21) Published: 2003-02-15 Authors: Washburn B, Weigand MA, Grosse-Wilde A, Janke M, Stahl H, Rieser E, Sprick MR, Schirrmacher V, Walczak H ABSTRACT The Newcastle disease virus (NDV) has antineoplastic and immunostimulatory properties, and it is currently clinically […]
Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-01-01 / Int. J. Cancer 2003 Jan;103(1):73-83PMID: 12455056 Journal: International journal of cancer (volume: 103, issue: 1, Int. J. Cancer 2003 Jan;103(1):73-83) Published: 2003-01-01 Authors: Bai L, Beckhove P, Feuerer M, Umansky V, Choi C, Solomayer FS, Diel IJ, Schirrmacher V ABSTRACT Dendritic cells (DC) and T cells were generated from Ficoll separated bone marrow (BM) mononuclear cells of primary operated […]
Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer
/in Breast Cancer, International Publications /von 2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):174-80PMID: 12538466 Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (volume: 9, issue: 1, Clin. Cancer Res. 2003 Jan;9(1):174-80) Published: 2003-01-01 Authors: Solomayer EF, Feuerer M, Bai L, Umansky V, Beckhove P, Meyberg GC, Bastert G, Schirrmacher V, Diel IJ ABSTRACT PURPOSE: Bone marrow is a special compartment […]
Editorial von Prof. Dr. Volker Schirrmacher zum Beitrag „Immuntherapeutische Strategien zur Behandlung solider Tumoren“
/in IOZK Veröffentlichungen /von IOZKEditorial von Prof. Dr. Volker Schirrmacher zum Beitrag „Immuntherapeutische Strategien zur Behandlung solider Tumoren“ von Dr. Christoph Renner, erschienen im Deutschen Ärzteblatt Editorial von Prof. Dr. Volker Schirrmacher (Deutsches Ärzteblatt) Beitrag als PDF (Deutsches Ärzteblatt) Wissenschaftliche Publikationen von Prof. Dr. Schirrmacher
Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis
/in Breast Cancer, Colorectal Cancer, Glioblastoma, International Publications, Newcastle Disease Virus /von 2002-07-01 / Int. J. Oncol. 2002 Jul;21(1):85-93PMID: 12063554 Journal: International journal of oncology (volume: 21, issue: 1, Int. J. Oncol. 2002 Jul;21(1):85-93) Published: 2002-07-01 Authors: Washburn B, Schirrmacher V ABSTRACT In order to analyse immune-stimulatory effects of infection of human tumor cells with Newcastle Disease Virus (NDV), gamma-irradiated human breast carcinoma, colon-carcinoma or glioblastoma cells from defined cell lines were modified […]
Beitrag mit Prof. Dr. Schirrmacher über den Stellenwert der Dendritischen Zellen im Einsatz gegen Krebszellen
/in Externe Meldungen, IOZK In der Presse /von IOZK„Forscher rücken einer Impfung gegen Krebszellen näher.“ Dieser Beitrag im Deutschlandfunk mit Prof. Schirrmacher informiert über den Stellenwert der Dendritischen Zellen im Einsatz gegen Krebszellen Radio-Beitrag (Deutschlandfunk)
Generation of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells
/in Dendritic Cells, International Publications /von 2002-02-01 / Int. J. Oncol. 2002 Feb;20(2):247-53PMID: 11788884 Journal: International journal of oncology (volume: 20, issue: 2, Int. J. Oncol. 2002 Feb;20(2):247-53) Published: 2002-02-01 Authors: Bai L, Feuerer M, Beckhove P, Umansky V, Schirrmacher V ABSTRACT Dendritic cells (DCs) currently used for vaccination in clinical studies to induce immunity against malignant cells are normally generated from peripheral blood-derived monocytes. Here we […]
Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects
/in International Publications, Newcastle Disease Virus /von 2001-05-01 / Int. J. Oncol. 2001 May;18(5):945-52PMID: 11295039 Journal: International journal of oncology (volume: 18, issue: 5, Int. J. Oncol. 2001 May;18(5):945-52) Published: 2001-05-01 Authors: Schirrmacher V, Griesbach A, Ahlert T ABSTRACT Newcastle Disease Virus (NDV) has interesting anti-neoplastic and pleiotropic immune stimulatory properties. The virus preferentially replicates in and kills tumor cells and appears to be safe and to varying […]
Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures
/in International Publications, Newcastle Disease Virus /von 1999-02-01 / Int. J. Oncol. 1999 Feb;14(2):205-15PMID: 9917494 Journal: International journal of oncology (volume: 14, issue: 2, Int. J. Oncol. 1999 Feb;14(2):205-15) Published: 1999-02-01 Authors: Schirrmacher V, Jurianz K, Roth C, Griesbach A, Bonifer R, Zawatzky R ABSTRACT Effects of tumor stimulator cell modification by infection with Newcastle Disease Virus (NDV) are described as analysed in vitro in mixed lymphocyte tumor […]
Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 1999-01-01 / Gene Ther. 1999 Jan;6(1):63-73PMID: 10341877 Journal: Gene therapy (volume: 6, issue: 1, Gene Ther. 1999 Jan;6(1):63-73) Published: 1999-01-01 Authors: Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C ABSTRACT Direct infection of tumor cells with viruses transferring protective or therapeutic genes, a frequently used procedure for production of tumor vaccines in human gene therapy, is […]
Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus
/in International Publications, Newcastle Disease Virus /von 1998-12-01 / Int. J. Oncol. 1998 Dec;13(6):1105-15PMID: 9824618 Journal: International journal of oncology (volume: 13, issue: 6, Int. J. Oncol. 1998 Dec;13(6):1105-15) Published: 1998-12-01 Authors: Haas C, Ertel C, Gerhards R, Schirrmacher V ABSTRACT We demonstrate in this study that infection of tumor cells by Newcastle Disease Virus (NDV) leads to changes in tumor cell surface adhesiveness and tumor immune costimulatory […]
Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
/in Breast Cancer, International Publications, Newcastle Disease Virus, Ovarian Cancer /von 1997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-66PMID: 9193327 Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (volume: 15, issue: 4, J. Clin. Oncol. 1997 Apr;15(4):1354-66) Published: 1997-04-01 Authors: Ahlert T, Sauerbrei W, Bastert G, Ruhland S, Bartik B, Simiantonaki N, Schumacher J, Häcker B, Schumacher M, Schirrmacher V ABSTRACT PURPOSE: We investigated quality and […]